guest ::
| Home > Publications database > Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. |
| Home > Publications database > Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors. |
| Journal Article | DKFZ-2025-00591 |
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
2025
Elsevier
Amsterdam
This record in other databases: 
Please use a persistent id in citations: doi:10.1016/j.medj.2025.100612
Abstract: Thymic epithelial tumors (TETs) are rare malignancies with limited treatment options and underexplored molecular features.We examined the genomic landscape and therapeutic outcomes in 81 patients with advanced TETs, including thymic carcinomas (TCs), thymomas, and thymic neuroendocrine neoplasms (TNENs), who were enrolled in the MASTER trial, a prospective observational precision oncology trial.Using whole-genome-sequencing and whole-exome-sequencing analysis, transcriptome analysis, and methylome analysis, we identified distinct molecular features across TET subtypes, including a higher tumor mutational burden in TC and pathogenic germline variants in 18% of cases. We performed transcriptome- and methylome-based unsupervised clustering and were able to divide TCs into immunologically hot and cold subsets, with hot TCs exhibiting higher T cell infiltration and significantly longer overall survival. In 65 out of 76 (86%) patients, we recommended molecularly informed therapies, which were applied in 29 out of 65 (45%) cases, leading to a disease control rate of 62% and an objective response rate of 23% (both n = 26). The progression-free survival ratio (PFSr) was > 1.3 in 8 out of 24 (33%) patients, 7 of them having TC. Among TCs, patients achieved a mean PFSr of 1.4, indicating potential therapeutic advantages in this subgroup. The PFSr between the PFS of immune checkpoint inhibition and preceding therapies was significantly higher in the hot cluster compared to the cold cluster (median 1.7 vs. 0.3; p = 0.01945).Our findings expand the understanding of TET biology and emphasize the role of precision oncology in informing treatment decisions and improving outcomes for patients with advanced TETs, particularly in TCs.
Keyword(s): Translation to patients ; molecular profiling ; multiomics ; precision oncology ; prospective observational study ; targeted therapy ; thymic carcinoma ; thymic epithelial tumor ; thymic neuroendocrine neoplasm ; thymoma ; whole-genome sequencing
; Clarivate Analytics Master Journal List ; Emerging Sources Citation Index ; IF >= 15 ; JCR ; SCOPUS ; Web of Science Core Collection
|
The record appears in these collections: |
